Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Equity (2020 - 2025)

Historic Return on Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 15.14%.

  • Insight Molecular Diagnostics' Return on Equity rose 168300.0% to 15.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.14%, marking a year-over-year increase of 168300.0%. This contributed to the annual value of 14.9% for FY2024, which is 147900.0% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Return on Equity stood at 15.14%, which was up 168300.0% from 11.27% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Return on Equity ranged from a high of 56.98% in Q1 2025 and a low of 11.27% during Q2 2025
  • Moreover, its 5-year median value for Return on Equity was 0.57% (2024), whereas its average is 6.68%.
  • The largest annual percentage gain for Insight Molecular Diagnostics' Return on Equity in the last 5 years was 575500bps (2025), contrasted with its biggest fall of -104700bps (2025).
  • Over the past 5 years, Insight Molecular Diagnostics' Return on Equity (Quarter) stood at 0.82% in 2021, then decreased by -27bps to 1.04% in 2022, then soared by 90bps to 0.1% in 2023, then soared by 47227bps to 47.52% in 2024, then crashed by -68bps to 15.14% in 2025.
  • Its last three reported values are 15.14% in Q3 2025, 11.27% for Q2 2025, and 56.98% during Q1 2025.